Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Angina Pectoris D000787 27 associated lipids
Angina Pectoris, Variant D000788 3 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Aortic Arch Syndromes D001015 2 associated lipids
Aortic Rupture D001019 3 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Weiss K [Calcium antagonists: anti-atherosclerotic effect by modification of the prostaglandin system]. 1988 Wien. Klin. Wochenschr. pmid:3071922
Kaliman J et al. [Venous prostacycline synthesis and plasma thromboxane B2 after low-dose aspirin]. 1983 Wien. Klin. Wochenschr. pmid:6359724
Sinzinger H and Firbas W [Cells of the vascular wall synthesize thromboxane]. 1983 Wien. Klin. Wochenschr. pmid:6369802
di Minno G et al. The binding of fibrinogen to platelets in diabetes mellitus. 1986 Wien. Klin. Wochenschr. pmid:3010580
Oettinger W et al. [Thromboxane A2 and granulocyte elastase after severe trauma--relationship to complications and survival rates]. 1989 Wien. Klin. Wochenschr. pmid:2609665
Gorczynska E et al. [Effect of various stimulators on cyclooxygenase activity, platelet aggregation and TxB2 synthesis after using a platelet inhibitor (Aspro Clear) in vivo and in vitro]. 1985 Wiad. Lek. pmid:3933184
Glushko LV et al. [An evaluation of the efficacy of antiatherosclerotic agents based on a study of the peripheral blood monocytes]. 1990 Vrach Delo pmid:2168603
Efimov VV and LadnyÄ­ AI [Status of the prostacyclin and thromboxane system, lipid metabolism and lipid peroxidation processes in patients with coronary atherosclerosis]. 1986 Vrach Delo pmid:3754994
Aliavi AL [Thrombocyte function and the prostacyclin-thromboxane system in patients with acute myocardial infarct]. 1988 Vrach Delo pmid:3293319
Bagdasarian A et al. IVIG adverse reactions: potential role of cytokines and vasoactive substances. 1998 Vox Sang. pmid:9501404
Jacobi K et al. Plasma levels of eicosanoids after transfusion of intraoperatively salvaged blood. 2000 Vox Sang. pmid:10729809
Bassalyk LS et al. [The effect of indomethacin and leukinferon on the thromboxane B2 level in the blood plasma of patients with endometrial cancer in the perioperative period]. 1992 Vopr Onkol pmid:1300754
Malý J et al. [Changes in platelet function in patients with arterial hypertension]. 1995 Vnitr Lek pmid:7571480
Spinarová L et al. [Physical training in patients with chornic heart failure: haemodynamics, effects]. 2001 Vnitr Lek pmid:15635849
Margolis JH et al. The efficacy of dexamethasone and flunixin meglumine in treating endotoxin-induced changes in calves. 1987 Vet. Res. Commun. pmid:3445446
Atroshi F et al. Inflammation-related changes in cyclic AMP and cyclic GMP in bovine mastitis. 1989 Vet. Res. Commun. pmid:2561035
Cheng Z et al. Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. 1997 Vet. Rec. pmid:9123796
Friton GM et al. Clinical and anti-inflammatory effects of treating endotoxin-challenged pigs with meloxicam. 2006 Vet. Rec. pmid:17056651
McKellar QA et al. Flunixin pharmacokinetics and serum thromboxane inhibition in the dog. 1989 Vet. Rec. pmid:2763429
Galbraith EA and McKellar QA Pharmacokinetics and pharmacodynamics of piroxicam in dogs. 1991 Vet. Rec. pmid:1887556
Mustonen K et al. Dose-response investigation of oral ketoprofen in pigs challenged with Escherichia coli endotoxin. 2012 Vet. Rec. pmid:22735989
Banting A et al. Efficacy of oral and parenteral ketoprofen in lactating cows with endotoxin-induced acute mastitis. 2008 Vet. Rec. pmid:18953074
Taylor PM et al. Pharmacodynamics and pharmacokinetics of flunixin in the cat: a preliminary study. 1991 Vet. Rec. pmid:2035219
Giri SN et al. Effects of endotoxin infusion on circulating levels of eicosanoids, progesterone, cortisol, glucose and lactic acid, and abortion in pregnant cows. 1990 Vet. Microbiol. pmid:2407024
Van de Weerdt ML et al. Ketoprofen and phenylbutazone attenuation of PAF-induced lung inflammation in calves. 1999 Vet. J. pmid:10030127
Lees P et al. Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. 1998 Vet. J. pmid:9638074
Maddens BE et al. Validation of immunoassays for the candidate renal markers C-reactive protein, immunoglobulin G, thromboxane B2 and retinol binding protein in canine urine. 2010 Vet. Immunol. Immunopathol. pmid:19815297
Hall JA et al. Dietary fish oil alters the lysophospholipid metabolomic profile and decreases urinary 11-dehydro thromboxane Bâ‚‚ concentration in healthy Beagles. 2011 Vet. Immunol. Immunopathol. pmid:21925741
Sigel MM et al. Phylogenetic studies on lymphokines. Fish lymphocytes respond to human IL-1 and epithelial cells produce an IL-1 like factor. 1986 Vet. Immunol. Immunopathol. pmid:3490047
Peters SM et al. In vivo characterization of inflammatory biomarkers in swine and the impact of flunixin meglumine administration. 2012 Vet. Immunol. Immunopathol. pmid:22648045
Bailey SR et al. Plasma concentrations of endotoxin and platelet activation in the developmental stage of oligofructose-induced laminitis. 2009 Vet. Immunol. Immunopathol. pmid:19091426
Moore RM et al. Effect of platelet-activating factor antagonist L-691,880 on low-flow ischemia-reperfusion injury of the large colon in horses. 1998 Jan-Feb Vet Surg pmid:9449176
Higgins AJ et al. Actions of BW540C in an equine model of acute inflammation: a preliminary study. 1987 Vet Q pmid:3039716
Dinev D and Andonova M The effect of general anesthesia and abdominal surgery upon plasma thromboxane B concentrations in horses. 2004 Vet Anaesth Analg pmid:15053753
Mullins KB et al. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. 2012 Vet Anaesth Analg pmid:22248445
Brezitskaia ON and Sedov KR [Status of the thrombocytic-vascular component of the hemostasis system in the population of the Far North]. 1991 Vestn. Akad. Med. Nauk SSSR pmid:1801462
Polkanov VS and Vinogradov AI [The content of thromboxane B2 and 6-ketoprostaglandin F1 alpha of the blood plasma in patients with psoriasis and children with allergic dermatoses]. 1989 Vestn Dermatol Venerol pmid:2718610
Zhou Z et al. Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors. 2015 Vascul. Pharmacol. pmid:25921923
Miyamoto A et al. Ibuprofen or ozagrel increases NO release and l-nitro arginine induces TXA(2) release from cultured porcine basilar arterial endothelial cells. 2007 Vascul. Pharmacol. pmid:17113355
González-Correa JA et al. Gender differences in the effect of aspirin on retinal ischemia, prostanoid synthesis and nitric oxide production in experimental type 1-like diabetes. 2007 Aug-Sep Vascul. Pharmacol. pmid:17581795
Park WH et al. Anti-inflammatory effects of a traditional Korean herbal formulation, Silsosangami, consisting of seven medicinal herbs: effect on hemolysis, neutrophil function, and gene expressions of iNOS and COX-2. 2004 Vascul. Pharmacol. pmid:15664882
Sinzinger H et al. 20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease? 1988 VASA pmid:3369232
Strobl-Jäger E et al. Platelet half-life in comparison to other in-vivo platelet function parameters such as thromboxane B2, beta-thromboglobulin and platelet factor 4 in patients with atherosclerotic lesions with and without hyperlipoproteinemia. 1986 VASA pmid:2948337
Ditter H and Matthias FR Changes in thromboxane formation by platelets during and after a continuous endotoxin infusion into rabbits. 1984 VASA pmid:6516562
Fitscha P et al. Follow-up of in-vivo platelet function (platelet half-life, thromboxane B2) in patients with coronary heart disease. 1984 VASA pmid:6516563
Rebrov BA [Role of thromboxane A2 (B2) in the pathogenesis of stress proteinuria in healthy persons]. 2001 Mar-Apr Urologiia pmid:11490711
Frøkiaer J et al. Renal blood flow and pelvic pressure after 4 weeks of total upper urinary tract obstruction in the pig. The effect of a TxA2 synthetase inhibitor on active preglomerular vasoconstriction. 1988 Urol. Res. pmid:3413908
Ali M et al. Urothelial synthesis of prostanoids in the ovine ureter. 1998 Urol. Res. pmid:9694598
Greenstein A et al. The role of oxygen free radicals and prostaglandins in reperfusion injury to warm ischemic kidneys. 1991 Urol. Res. pmid:1759334
RogovyÄ­ IuE [Beta 2-microglobulin as a criterion of dysfunction in the regulation of proximal tubular activity in mercuric chloride-induced nephropathy]. 1998 May-Jun Urol Nefrol (Mosk) pmid:9644989